

10/634,709


2

PC25236A

AMENDMENTS TO THE ABSTRACT

Please replace the Abstract with the below amended abstract:

This invention provides compounds defined by Formula I



or a and pharmaceutically acceptable salt salts thereof,
wherein ~~R¹, Q, S, T, U, V, and R²~~ are as defined in the specification. The invention also
provides and pharmaceutical compositions comprising a compound of Formula I, or a
pharmaceutically acceptable salt thereof, as defined in the specification, together with a
pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides
~~methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the~~
~~animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The~~
~~invention also provides methods of treating a disease mediated by an MMP-13 enzyme in~~
~~a patient, comprising administering to the patient a compound of Formula I, or a~~
~~pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical~~
~~composition. The invention also provides methods of treating diseases such as heart~~
~~disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or~~
~~rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-~~
~~related macular degeneration, chronic obstructive pulmonary disease, asthma,~~
~~periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient,~~
~~comprising administering to the patient a compound of Formula I, or a pharmaceutically~~
~~acceptable salt thereof, either alone or in a pharmaceutical composition. The invention~~
~~also provides combinations, comprising a compound of Formula I, or a pharmaceutically~~
~~acceptable salt thereof, together with another pharmaceutically active component as~~
~~described in the specification.~~